Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects

Clinical Pharmacology in Drug Development

Volumn 5, Issue 1, 2016, Pages 57-68

  Tillner, Joachim ^a   Lehmann, Anne ^a   Paehler, Tobias ^a   Lukacs, Zoltan ^b   Ruf, Sven ^a   Sadowski, Thorsten ^a   Pinquier, Jean Louis ^c   Ruetten, Hartmut ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c SANOFI   (France)

Author keywords

Cathepsin A; First in man; Healthy subjects; Renal kallikrein kinin system; galactosidase

Indexed keywords

BETA GALACTOSIDASE; CARBOXYPEPTIDASE C; CYSTEINE PROTEINASE INHIBITOR; PLACEBO; SAR 164653; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; ADOLESCENT; AGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; HALF LIFE TIME; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CATHEPSIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84955205182     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.201     Document Type: Article

References (22)

1. Hiraiwa M. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein. Cell Mol Life Sci. 1999; 56:894-907.
2. Galjart NJ, Morreau H, Willemsen R, Gillemans N, Bonten EJ, d'Azzo A. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J Biol Chem. 1991; 266:14754-4762.
3. D'Azzo A, Hoogeveen AT, Reuser JJ, Robinson H, Galjaard H. Molecular defect in combined b-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci. 1982; 79:4535-4539.
4. Zhou XY, van der Spoel A, Rottier R, et al. Molecular and biochemical analysis of protective protein/cathepsin A mutations: correlation with clinical severity of galactosialidosis. Hum Mol Genet. 1996; 5:1977-1987.
5. Seyrantepe V, Hinek A, Peng J, et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin A) is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation. 2008; 117:1973-1981.
6. Satake A, Itoh K, Shimmoto M, Saido TC, Sakuraba H, Suzuki Y. Distribution of lysosomal protective protein in human tissues. Biochem Biophys Res Commun. 1994; 205(1):38-43.
7. Sohma O, Mizuguchi M, Takashima S et al. Expression of protective protein in human tissue. Pediatr Neurol. 1999; 20(3):210-214.
8. Ruf S, Buning C, Schreuder H, et al. Novel β-Amino Acid Derivatives as Inhibitors of Cathepsin A. J Med Chem. 2012; 55(17):7636-7649.
9. Ruf S, Buning C, Schreuder H, et al. Inhibition of CatA: an emerging strategy for the treatment of heart failure. Future Med Chem. 2013; 5(4):399-409.
10. Majima M, Kuribayashi Y, Ikeda Y, et al. Diuretic and natriuretic effect of ebelactone B in anesthetized rats by inhibition of a urinary carboxypeptidase Y-like kininase. Jpn J Pharmacol. 1994; 65(1):79-82.
11. Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kininase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol. 1999; 126:613-620.
12. Saito M, Majima M, Katori M, et al. Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon. Int J Tissue React. 1995; 17:181-190.
13. Jackman HL, Massad MG, Sekosan M, et al. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension. 2002; 39(5):976-981.
14. Lukacs Z, Keil A, Peters V, et al. Towards quality assurance in the determination of lysosomal enzymes: a two-centre study. J Inherit Metab Dis. 2003; 26(6):571-581.
15. Pshezhetsky A, Hinek A. Serine carboxypeptidases in Regulation of Vasoconstriction and Elastogenesis. Trends Cardiovasc Med. 2009; 19:11-17.
16. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2007; 50:247-256.
17. Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006; 387:665-675.
18. Carretero OA, Scicli AG. The renal kallikrein-kinin system. Am J Physiol. 1980; 238:F247-255.
19. Campbell DJ. Towards understanding the kallikrein-kinin system: insights from measurements of kinin peptides. Braz J Med Biol Res. 2000; 33:665-677.
20. Margolius HS. The kallikrein-kinin system and the kidney. Annu Rev Physiol. 1984; 46:309-326.
21. Katori M, Majima M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol. 1996; 70(2):95-128.
22. Katori M, Majima M. The renal kallikrein-kinin system: Its role as a safety valve for excess sodium uptake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit Rev Clin Lab Sci. 2003; 40(1):43-115.